**Exhibit 99.1**

CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)

The following illustrates revised reportable segment revenue information for the periods indicated:

| | Fiscal Year Ended September 30, 2026 | | | | |
|---|---|---|---|---|---|
| **Revenue** | **First Quarter** | **Second Quarter** | **Third Quarter** | **Fourth Quarter** | **Fiscal Year** |
| | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** |
| Pharmaceutical Distribution and Services | $ 72,969,277 | $ 66,108,390 | $ 71,164,265 | $ 74,242,224 | $ 284,484,156 |
| Specialty Pharmaceutical and Provider Services | 11,098,508 | 10,471,417 | 11,645,430 | 12,175,177 | 45,390,532 |
| Other | 2,128,947 | 2,055,571 | 2,253,330 | 2,302,073 | 8,739,921 |
| Intersegment eliminations | (264,716) | (279,462) | (308,188) | (364,944) | (1,217,310) |
| **Total revenue** | $ 85,932,016 | $ 78,355,916 | $ 84,754,837 | $ 88,354,530 | $ 337,397,299 |

| | Fiscal Year Ended September 30, 2025 | | | | |
|---|---|---|---|---|---|
| **Revenue** | **First Quarter** | **Second Quarter** | **Third Quarter** | **Fourth Quarter** | **Fiscal Year** |
| | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** |
| Pharmaceutical Distribution and Services | $ 69,441,734 | $ 63,350,601 | $ 67,700,658 | $ 71,352,299 | $ 271,845,292 |
| Specialty Pharmaceutical and Provider Services | 10,490,286 | 10,418,900 | 11,136,471 | 10,542,389 | 42,588,046 |
| Other | 2,002,455 | 1,956,407 | 2,107,464 | 2,091,507 | 8,157,833 |
| Intersegment eliminations | (447,415) | (272,235) | (281,061) | (257,641) | (1,258,352) |
| **Total revenue** | $ 81,487,060 | $ 75,453,673 | $ 80,663,532 | $ 83,728,554 | $ 321,332,819 |

CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)

The following illustrates revised reportable segment operating income and margin information for the periods indicated:

| | Fiscal Year Ended September 30, 2026 | | | | |
|---|---|---|---|---|---|
| **Operating income** | **First Quarter** | **Second Quarter** | **Third Quarter** | **Fourth Quarter** | **Fiscal Year** |
| | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** |
| Pharmaceutical Distribution and Services | $ 606,904 | $ 774,786 | $ 664,122 | $ 690,546 | $ 2,736,358 |
| Specialty Pharmaceutical and Provider Services | 366,582 | 399,311 | 467,908 | 459,221 | 1,693,022 |
| Other | 91,417 | 91,633 | 108,736 | 101,075 | 392,861 |
| Intersegment eliminations | (2,189) | (2,381) | (2,680) | (1,944) | (9,194) |
| **Total segment operating income** | $ 1,062,714 | $ 1,263,349 | $ 1,238,086 | $ 1,248,898 | $ 4,813,047 |
| | | | | | |
| Percentages of revenue: | | | | | |
| | | | | | |
| **Pharmaceutical Distribution and Services** | | | | | |
| Gross profit | 2.26% | 2.70% | 2.39% | 2.31% | 2.41% |
| Operating expenses | 1.43% | 1.52% | 1.45% | 1.38% | 1.45% |
| Operating income | 0.83% | 1.17% | 0.93% | 0.93% | 0.96% |
| | | | | | |
| **Specialty Pharmaceutical and Provider Services** | | | | | |
| Gross profit | 9.21% | 12.27% | 12.89% | 12.58% | 11.76% |
| Operating expenses | 5.91% | 8.45% | 8.88% | 8.81% | 8.03% |
| Operating income | 3.30% | 3.81% | 4.02% | 3.77% | 3.73% |
| | | | | | |
| **Other** | | | | | |
| Gross profit | 15.24% | 15.16% | 14.58% | 14.30% | 14.81% |
| Operating expenses | 10.95% | 10.70% | 9.76% | 9.91% | 10.31% |
| Operating income | 4.29% | 4.46% | 4.83% | 4.39% | 4.50% |

CENCORA, INC.
SUMMARY REPORTABLE SEGMENT INFORMATION
(in thousands)
(unaudited)

| | Fiscal Year Ended September 30, 2025 | | | | |
|---|---|---|---|---|---|
| **Operating income** | **First Quarter** | **Second Quarter** | **Third Quarter** | **Fourth Quarter** | **Fiscal Year** |
| | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** | **(As Revised)** |
| Pharmaceutical Distribution and Services | $ 569,446 | $ 725,639 | $ 590,995 | $ 614,651 | $ 2,500,731 |
| Specialty Pharmaceutical and Provider Services | 282,531 | 373,741 | 380,246 | 333,989 | 1,370,507 |
| Other | 97,329 | 92,851 | 87,104 | 74,429 | 351,713 |
| Intersegment eliminations | 2 | 33 | (14) | 1 | 22 |
| **Total segment operating income** | $ 949,308 | $ 1,192,264 | $ 1,058,331 | $ 1,023,070 | $ 4,222,973 |
| | | | | | |
| Percentages of revenue: | | | | | |
| | | | | | |
| **Pharmaceutical Distribution and Services** | | | | | |
| Gross profit | 2.27% | 2.62% | 2.33% | 2.28% | 2.37% |
| Operating expenses | 1.45% | 1.47% | 1.46% | 1.42% | 1.45% |
| Operating income | 0.82% | 1.15% | 0.87% | 0.86% | 0.92% |
| | | | | | |
| **Specialty Pharmaceutical and Provider Services** | | | | | |
| Gross profit | 6.14% | 9.01% | 8.67% | 9.23% | 8.27% |
| Operating expenses | 3.44% | 5.42% | 5.26% | 6.07% | 5.05% |
| Operating income | 2.69% | 3.59% | 3.41% | 3.17% | 3.22% |
| | | | | | |
| **Other** | | | | | |
| Gross profit | 15.86% | 16.27% | 14.95% | 14.57% | 15.40% |
| Operating expenses | 11.00% | 11.53% | 10.82% | 11.01% | 11.08% |
| Operating income | 4.86% | 4.75% | 4.13% | 3.56% | 4.31% |